Unknown

Dataset Information

0

Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach.


ABSTRACT: In September 2019, the U.S. Food and Drug Administration approved oral semaglutide as the first orally administered glucagon-like peptide 1 (GLP-1) receptor agonist for treating people with type 2 diabetes. Although injectable GLP-1 receptor agonists are well-established treatment options for people with type 2 diabetes, clinical experience with an oral formulation in this class is limited. This article provides practical guidance for diabetes care and education specialists on how to effectively counsel patients initiating therapy with oral semaglutide on appropriate administration of the treatment and its possible effects on glycemic control, body weight, and quality of life. Strategies for mitigating potential side effects typical of the GLP-1 receptor agonist class, namely nausea, vomiting, and diarrhea, are also provided. Involving patients in treatment decisions and educating them about available and prescribed medications are key strategies for encouraging treatment adherence and ensuring optimal therapeutic outcomes.

SUBMITTER: Isaacs DM 

PROVIDER: S-EPMC7887531 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Optimizing Therapeutic Outcomes With Oral Semaglutide: A Patient-Centered Approach.

Isaacs Diana M DM   Kruger Davida F DF   Spollett Geralyn R GR  

Diabetes spectrum : a publication of the American Diabetes Association 20210101 1


In September 2019, the U.S. Food and Drug Administration approved oral semaglutide as the first orally administered glucagon-like peptide 1 (GLP-1) receptor agonist for treating people with type 2 diabetes. Although injectable GLP-1 receptor agonists are well-established treatment options for people with type 2 diabetes, clinical experience with an oral formulation in this class is limited. This article provides practical guidance for diabetes care and education specialists on how to effectively  ...[more]

Similar Datasets

| S-EPMC6143220 | biostudies-literature
| S-EPMC7379603 | biostudies-literature
| S-EPMC8024801 | biostudies-literature
| S-EPMC4464901 | biostudies-literature
| S-EPMC10664446 | biostudies-literature
| S-EPMC10620693 | biostudies-literature
| S-EPMC8684610 | biostudies-literature
| S-EPMC8039427 | biostudies-literature
| S-EPMC10635329 | biostudies-literature
| S-EPMC5763323 | biostudies-literature